ES2441880B1 - COMPOSITION BASED ON POLIPEPTIDES FOR THE TREATMENT OF MIASIS - Google Patents

COMPOSITION BASED ON POLIPEPTIDES FOR THE TREATMENT OF MIASIS Download PDF

Info

Publication number
ES2441880B1
ES2441880B1 ES201231063A ES201231063A ES2441880B1 ES 2441880 B1 ES2441880 B1 ES 2441880B1 ES 201231063 A ES201231063 A ES 201231063A ES 201231063 A ES201231063 A ES 201231063A ES 2441880 B1 ES2441880 B1 ES 2441880B1
Authority
ES
Spain
Prior art keywords
treatment
myiasis
composition based
present
miasis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
ES201231063A
Other languages
Spanish (es)
Other versions
ES2441880A1 (en
Inventor
Antonio Osuna Carrillo de Albornoz
Gloria Maribel GONZÁLEZ GONZÁLEZ
Argentina YING
Gilberto ESKILDSEN
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Universidad De Panama
Universidad de Granada
DE PANAMA, University of
Original Assignee
Universidad De Panama
Universidad de Granada
DE PANAMA, University of
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Universidad De Panama, Universidad de Granada, DE PANAMA, University of filed Critical Universidad De Panama
Priority to ES201231063A priority Critical patent/ES2441880B1/en
Priority to PCT/ES2013/070481 priority patent/WO2014006262A1/en
Publication of ES2441880A1 publication Critical patent/ES2441880A1/en
Application granted granted Critical
Publication of ES2441880B1 publication Critical patent/ES2441880B1/en
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/45—Transferases (2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0003—Invertebrate antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Composición basada en polipéptidos para el tratamiento de miasis.#La presente invención describe fragmentos de péptidos homólogos a aquellos presentes en la secuencia de la arginina quinasa que pueden conferir inmunidad protectora en mamíferos contra la infección por larvas de insectos dípteros capaces de provocar miasis. La presente invención también describe composiciones basadas en dichos péptidos para su uso como vacuna frente a miasis.Composition based on polypeptides for the treatment of myiasis. # The present invention describes peptide fragments homologous to those present in the arginine kinase sequence that can confer protective immunity in mammals against infection by larvae of diptera insects capable of causing myiasis. The present invention also describes compositions based on said peptides for use as a vaccine against myiasis.

Description



imagen1image 1

imagen2image2

imagen3image3

imagen4image4

imagen5image5

imagen6image6

imagen7image7

imagen8image8

imagen9image9

imagen10image10

imagen11image11

imagen12image12

imagen13image13

imagen14image14

imagen15image15

imagen16image16

imagen17image17

imagen18image18

imagen19image19

imagen20image20

imagen21image21

imagen22image22

imagen23image23

imagen24image24

imagen25image25

imagen26image26

imagen27image27

imagen28image28

imagen29image29

imagen30image30

imagen31image31

imagen32image32

imagen33image33

imagen34image34

imagen35image35

imagen36image36

imagen37image37

imagen38image38

imagen39image39

imagen40image40

imagen41image41

imagen42image42

imagen43image43

imagen44image44

imagen45image45

imagen46image46

imagen47image47

imagen48image48

imagen49image49

imagen50image50

imagen51image51

imagen52image52

imagen53image53

imagen54image54

imagen55image55

imagen56image56

imagen57image57

Claims (1)



 imagen1image 1 imagen2image2 imagen3image3 imagen4image4 imagen5image5 imagen6image6
ES201231063A 2012-07-06 2012-07-06 COMPOSITION BASED ON POLIPEPTIDES FOR THE TREATMENT OF MIASIS Expired - Fee Related ES2441880B1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
ES201231063A ES2441880B1 (en) 2012-07-06 2012-07-06 COMPOSITION BASED ON POLIPEPTIDES FOR THE TREATMENT OF MIASIS
PCT/ES2013/070481 WO2014006262A1 (en) 2012-07-06 2013-07-06 Composition containing polypeptides for the treatment of myiasis

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ES201231063A ES2441880B1 (en) 2012-07-06 2012-07-06 COMPOSITION BASED ON POLIPEPTIDES FOR THE TREATMENT OF MIASIS

Publications (2)

Publication Number Publication Date
ES2441880A1 ES2441880A1 (en) 2014-02-06
ES2441880B1 true ES2441880B1 (en) 2014-11-13

Family

ID=49881403

Family Applications (1)

Application Number Title Priority Date Filing Date
ES201231063A Expired - Fee Related ES2441880B1 (en) 2012-07-06 2012-07-06 COMPOSITION BASED ON POLIPEPTIDES FOR THE TREATMENT OF MIASIS

Country Status (2)

Country Link
ES (1) ES2441880B1 (en)
WO (1) WO2014006262A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016183500A1 (en) * 2015-05-14 2016-11-17 La Jolla Institute For Allergy And Immunology Novel antigens and t cell epitopes from cockroach and methods of making and using same

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZW8893A1 (en) * 1992-07-21 1994-06-01 Pitman Moore Inc Vaccines
US20090036653A1 (en) * 2006-04-13 2009-02-05 Peptimmune, Inc. Methods for the directed expansion of epitopes for use as antibody ligands
EP2586460A1 (en) * 2007-10-16 2013-05-01 Peptimmune, Inc. Method for designing and preparing vaccines comprising directed sequence polymer composition via the directed expansion of epitopes
US9895411B2 (en) * 2010-06-29 2018-02-20 San Diego State University Research Foundation Analogs of C5a and methods of using same

Also Published As

Publication number Publication date
WO2014006262A1 (en) 2014-01-09
ES2441880A1 (en) 2014-02-06

Similar Documents

Publication Publication Date Title
CL2014002093A1 (en) Piperidinopyrimidine derivative compounds; pharmaceutical composition that includes them; Use in the treatment of viral infections.
CL2014001994A1 (en) Synthetic apeline mimetic polypeptide for treatment and heart failure; pharmaceutical composition comprising said polypeptide.
UY36180A (en) DIFLUOROMETIL-INDANIL-CARBOXAMIDAS NICOTÍNICAS
DK2940135T3 (en) Heterodimerized polypeptide
CL2014000291A1 (en) Vaccine comprising at least 30 amino acids of a p62 / sqstm1 polypeptide or a nucleic acid encoding it; and its use for the treatment and prophylaxis of cancer.
CL2014000806A1 (en) Compounds derived from 1-arylcarbonyl-4-oxy-piperidino; pharmaceutical composition that includes them; Use for the prevention or treatment of neurodegenerative diseases such as Alzheimer's disease, Parkinson's disease, Huntington's disease or multiple sclerosis.
ES2981865T3 (en) Conjugate comprising a cell-penetrating peptide and compositions comprising the same
DK2728002T3 (en) HETERODIMERIZED POLYPEPTIDE
DK2968477T3 (en) FACTOR VIII POLYPEPTID FORMULATIONS
GT201700124A (en) FORMULATION OF GLARGINE / LIXISENATIDA INSULIN FIXED RELATIONSHIP
ES2620754T3 (en) Use of 5-androstane (alkyl) -3,5,6-triol in the preparation of neuroprotective drugs
CL2015000615A1 (en) Compounds derived from 4-amino-quinolines, rip2 kinase inhibitors; pharmaceutical composition that includes them; use for the treatment of diseases such as crohn's disease, ulcerative colitis or blau syndrome.
CL2012003458A1 (en) Vector comprising a campylobacter antigenic polypeptide; pharmaceutical composition comprising said vector; use of the vector to improve the subject's immune response to the antigenic polypeptide.
AR083126A1 (en) VACCINE COMPOSITION FOR CONTROL OF INFESTATIONS BY ECTOPARASITES
CL2014000394A1 (en) Use of substituted phenyl-benzofuran-sulphonamide compounds for the treatment of hepatitis c virus (hcv); and pharmaceutical composition comprising these substituted phenyl-benzofuran-sulfamido compounds.
CL2014001862A1 (en) Compounds derived from substituted moropholinyl, useful as mogat-2 inhibitors; pharmaceutical composition that includes them; use in the treatment of hypertriglyceridemia.
DOP2017000287A (en) GLP-1 ANALOGS PROTEASA-RESISTANT LIPIDES
CO2017005983A2 (en) Pyridyl-cycloalkyl-substituted carboxylic acids, compositions containing them and uses thereof
CL2015001458A1 (en) Symbiotic composition and the use of it.
CL2015001881A1 (en) Compound 4-hydroxy-2-methyl-5- (propan-2-ylidene) cyclohexyl-3-en-1-carbaldehyde; use of the compound for the treatment of Alzheimer's disease; pharmaceutical composition; Method to prepare the composition.
CO6831981A2 (en) Medical products for use in diseases related to microbial infections in the upper aerodigestive tract
MX2015012905A (en) Recombinant factor viii formulations.
CL2014000509A1 (en) Co-crystals comprising ciprodinyl and dithianon; process to prepare the co-crystals; crop protection composition comprising said co-crystals; use to fight phytopathogenic hobgos.
BR112017024126A2 (en) pharmaceutical compositions and use thereof
ES2441880B1 (en) COMPOSITION BASED ON POLIPEPTIDES FOR THE TREATMENT OF MIASIS

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 2441880

Country of ref document: ES

Kind code of ref document: B1

Effective date: 20141113

FD2A Announcement of lapse in spain

Effective date: 20210915